News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
218,205 Results
Type
Article (4817)
Company Profile (100)
Press Release (213288)
Section
Business (63298)
Career Advice (98)
Deals (12035)
Drug Delivery (3)
Drug Development (34479)
Employer Resources (12)
FDA (3891)
Job Trends (3793)
News (113617)
Policy (8424)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Standard (2)
Academia (245)
Accelerated approval (11)
Allergies (66)
Alliances (16943)
ALS (74)
Alzheimer's disease (529)
Antibody-drug conjugate (ADC) (194)
Approvals (4227)
Artificial intelligence (128)
Autoimmune disease (123)
Automation (7)
Bankruptcy (55)
Best Places to Work (3236)
BIOSECURE Act (2)
Biosimilars (123)
Biotechnology (68)
Bladder cancer (70)
Brain cancer (25)
Breast cancer (203)
Cancer (1955)
Cardiovascular disease (110)
Career advice (92)
Career pathing (3)
CAR-T (101)
CDC (2)
Celiac Disease (1)
Cell therapy (228)
Cervical cancer (13)
Clinical research (31781)
Collaboration (750)
Compensation (750)
Complete response letters (18)
COVID-19 (562)
CRISPR (26)
C-suite (432)
Cystic fibrosis (38)
Data (3075)
Depression (72)
Dermatology (29)
Diabetes (149)
Diagnostics (977)
Digital health (7)
Diversity, equity & inclusion (2)
Drug discovery (82)
Drug pricing (12)
Drug shortages (1)
Duchenne muscular dystrophy (87)
Earnings (28818)
Editorial (3)
Employer branding (1)
Employer resources (11)
Events (39388)
Executive appointments (420)
FDA (5245)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (1)
Frontotemporal dementia (8)
Funding (455)
Gene editing (52)
Generative AI (7)
Gene therapy (117)
GLP-1 (254)
Government (618)
Grass and pollen (1)
Guidances (144)
Healthcare (2689)
HIV (30)
Huntington's disease (7)
IgA nephropathy (39)
Immunology and inflammation (55)
Immuno-oncology (29)
Indications (79)
Infectious disease (642)
Inflammatory bowel disease (83)
Inflation Reduction Act (1)
Influenza (31)
Intellectual property (109)
Interviews (13)
IPO (6421)
IRA (3)
Job creations (715)
Job search strategy (83)
JPM (5)
Kidney cancer (11)
Layoffs (36)
Leadership (2)
Legal (1534)
Liver cancer (37)
Longevity (7)
Lung cancer (324)
Lymphoma (179)
Machine learning (14)
Management (4)
Manufacturing (334)
MASH (107)
Medical device (1457)
Medtech (1473)
Mergers & acquisitions (6161)
Metabolic disorders (430)
mRNA (18)
Multiple sclerosis (72)
NASH (7)
Neurodegenerative disease (96)
Neuropsychiatric disorders (35)
Neuroscience (1066)
NextGen: Class of 2026 (893)
Non-profit (244)
Now hiring (5)
Obesity (153)
Opinion (24)
Ovarian cancer (64)
Pain (71)
Pancreatic cancer (78)
Parkinson's disease (118)
Partnered (3)
Patents (198)
Patient recruitment (274)
Peanut (21)
People (19294)
Pharmaceutical (31)
Pharmacy benefit managers (4)
Phase 1 (9279)
Phase 2 (14247)
Phase 3 (10684)
Pipeline (3361)
Policy (15)
Postmarket research (673)
Preclinical (3445)
Press Release (13)
Prostate cancer (91)
Psychedelics (4)
Radiopharmaceuticals (130)
Rare diseases (314)
Real estate (1457)
Recruiting (7)
Regulatory (8020)
Reports (12)
Research institute (289)
Resumes & cover letters (6)
Rett syndrome (1)
RNA editing (4)
RSV (17)
Schizophrenia (120)
Series A (76)
Series B (60)
Service/supplier (3)
Sickle cell disease (30)
Spinal muscular atrophy (47)
Sponsored (6)
Startups (1028)
State (1)
Stomach cancer (2)
Supply chain (27)
Tariffs (7)
Vaccines (185)
Venture capital (13)
Weight loss (44)
Women's health (17)
Worklife (1)
Date
Today (23)
Last 7 days (373)
Last 30 days (1084)
Last 365 days (11064)
2026 (4118)
2025 (11167)
2024 (12943)
2023 (14943)
2022 (19578)
2021 (20796)
2020 (18161)
2019 (11688)
2018 (8520)
2017 (10598)
2016 (8980)
2015 (11562)
2014 (8764)
2013 (6702)
2012 (6788)
2011 (6907)
2010 (6729)
Location
Africa (148)
Alabama (19)
Arizona (38)
Arkansas (3)
Asia (29348)
Australia (3546)
California (4885)
Canada (1121)
China (988)
Colorado (136)
Connecticut (217)
Delaware (217)
Europe (33022)
Florida (663)
Georgia (146)
Idaho (4)
Illinois (230)
India (49)
Indiana (157)
Iowa (9)
Japan (362)
Kansas (74)
Kentucky (10)
Louisiana (2)
Maine (6)
Maryland (474)
Massachusetts (3822)
Michigan (49)
Minnesota (180)
Mississippi (1)
Missouri (23)
Montana (1)
Nebraska (7)
Nevada (28)
New Hampshire (6)
New Jersey (1711)
New Mexico (4)
New York (1507)
North Carolina (602)
Northern California (2610)
Ohio (113)
Oklahoma (5)
Oregon (11)
Pennsylvania (848)
Puerto Rico (5)
Rhode Island (4)
South America (205)
South Carolina (6)
Southern California (1920)
Tennessee (18)
Texas (528)
United States (16894)
Utah (97)
Virginia (153)
Washington D.C. (16)
Washington State (303)
Wisconsin (24)
218,205 Results for "shenzhen hightide biopharmaceutical ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
March 10, 2026
·
5 min read
Press Releases
Faron Pharmaceuticals Ltd: Directorate Appointment
May 5, 2026
·
3 min read
Press Releases
Faron Pharmaceuticals Ltd: Termination of Liquidity Provision Service
May 6, 2026
·
2 min read
Press Releases
Faron Pharmaceuticals Ltd: Results of the Annual General Meeting
May 4, 2026
·
6 min read
Press Releases
Faron Pharmaceuticals Ltd: Director Dealing
March 19, 2026
·
3 min read
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
ROCKVILLE, MD and SHENZHEN, CHINA, HighTide Therapeutics, Inc. (Stock Code: 2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced that it will make multiple presentations at the European Association for the Study of the Liver (EASL) Congress, taking place from June 5-8, 2024 in Milan, Italy.
June 5, 2024
·
4 min read
Press Releases
QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
January 29, 2026
·
3 min read
Press Releases
FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity
May 4, 2026
·
4 min read
Press Releases
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
May 10, 2026
·
3 min read
Press Releases
Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
May 7, 2026
·
6 min read
1 of 21,821
Next
